Evidence suggests that monotherapy with an oral P2Y12 inhibitor after short DAPT regimens is related to myocardial infarction, all-cause mortality, and stroke risks in patients receiving complex PCI [21]. The gene discussed is P2RY12; the disease is myocardial infarction.